FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 19:57:46 25/06/2024 BST | ||
| 6.59 EUR | +1.54% |
|
| Current month | -12.13% | ||
| 1 month | -12.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 6.59 | +1.54% |
| 24/06/24 | 6.49 | -3.99% |
| 21/06/24 | 6.76 | +0.75% |
| 20/06/24 | 6.71 | -2.33% |
| 19/06/24 | 6.87 | +0.88% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 07:57 pm
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2LU5 |
| ISIN | DE000JK2LU53 |
| Date issued | 23/02/2024 |
| Strike | 633.3 $ |
| Maturity | Unlimited |
| Parity | 23.12 : 1 |
| Emission price | 10.07 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.61 € |
|---|---|
| Lowest since issue | 6.05 € |
| Spread | 0.2 € |
| Spread % | 2.95% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
